Niewczas Monika A, Ficociello Linda H, Johnson Amanda C, Walker William, Rosolowsky Elizabeth T, Roshan Bijan, Warram James H, Krolewski Andrzej S
Research Division of Joslin Diabetes Center, Boston, MA 02215, USA.
Clin J Am Soc Nephrol. 2009 Jan;4(1):62-70. doi: 10.2215/CJN.03010608. Epub 2008 Dec 10.
The aim of our study was to examine serum markers of the TNF and Fas pathways for association with cystatin-C based estimated glomerular filtration rate (cC-GFR) in subjects with type 1 diabetes (T1DM) and no proteinuria.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study group (the 2nd Joslin Kidney Study) comprised patients with T1DM and normoalbuminuria (NA) (n = 363) or microalbuminuria (MA) (n = 304). Impaired renal function (cC-GFR <90 ml/min) was present in only 10% of patients with NA and 36% of those with MA. We measured markers of the tumor necrosis factor alpha (TNFalpha) pathway [TNFalpha, soluble TNF receptor 1 (sTNFR1), and 2 (sTNFR2)], its downstream effectors [soluble intercellular and soluble vascular adhesion molecules (sICAM-1 and sVCAM-1), interleukin 8 (IL8/CXCL8), monocytes chemoattractant protein-1 (MCP1), and IFNgamma inducible protein-10 (IP10/CXCL10)], the Fas pathway [soluble Fas (sFas) and Fas ligand (sFasL)], CRP, and IL6.
Of these, TNFalpha, sTNFRs, sFas, sICAM-1, and sIP10 were associated with cC-GFR. However, only the TNF receptors and sFas were associated with cC-GFR in multivariate analysis. Variation in the concentration of the TNF receptors had a much stronger impact on GFR than clinical covariates such as age and albumin excretion.
Elevated concentrations of serum markers of the TNFalpha and Fas-pathways are strongly associated with decreased renal function in nonproteinuric type 1 diabetic patients. These effects are independent of those of urinary albumin excretion. Follow-up studies are needed to characterize the role of these markers in early progressive renal function decline.
我们研究的目的是在1型糖尿病(T1DM)且无蛋白尿的受试者中,检测肿瘤坏死因子(TNF)和Fas途径的血清标志物与基于胱抑素C估算的肾小球滤过率(cC-GFR)之间的关联。
设计、地点、参与者及测量方法:研究组(第2次乔斯林肾脏研究)包括T1DM且尿白蛋白正常(NA)(n = 363)或微量白蛋白尿(MA)(n = 304)的患者。仅10%的NA患者和36%的MA患者存在肾功能受损(cC-GFR <90 ml/分钟)。我们检测了肿瘤坏死因子α(TNFα)途径的标志物【TNFα、可溶性TNF受体-1(sTNFR1)和-2(sTNFR2)】、其下游效应分子【可溶性细胞间黏附分子和可溶性血管黏附分子(sICAM-1和sVCAM-1)、白细胞介素8(IL8/CXCL8)、单核细胞趋化蛋白-1(MCP1)以及γ干扰素诱导蛋白-10(IP10/CXCL10)】、Fas途径【可溶性Fas(sFas)和Fas配体(sFasL)】、C反应蛋白(CRP)和白细胞介素6(IL6)。
其中,TNFα、sTNFRs、sFas、sICAM-1和sIP10与cC-GFR相关。然而,多变量分析中仅TNF受体和sFas与cC-GFR相关。TNF受体浓度的变化对肾小球滤过率的影响比年龄和白蛋白排泄等临床协变量更强。
TNFα和Fas途径的血清标志物浓度升高与非蛋白尿性1型糖尿病患者肾功能下降密切相关。这些效应独立于尿白蛋白排泄的效应。需要进行后续研究以明确这些标志物在早期肾功能进行性下降中的作用。